wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 7. no 4. December 2002  
 TABLE OF CONTENT

 Original articles
Three months treatment with formoterol in mild asthma
Anna Dagmara Bareła, Jolanta Wrońska, A. Safianowska, Ryszarda Chazan

Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Samodzielny Publiczny Centralny Szpital Kliniczny Akademii Medycznej, ul. Banacha 1a, 02-097 Warszawa


Introduction. Formoterol is a long-acting b2-agonist, used in asthma management.
Aim of study. The aim of this study was to assess a three month period of treatment with formoterol, its influence on lung function, tolerability and side effects.
Material and methods. Eighteen patients with mild asthma, 11 women and 7 men, mean age 27.5, were recruited. Formoterol was given in a dose of 12 µg twice a day, in inhalation capsules. The patients underwent baseline studies as follows: spirometric parameters (FEV1, FVC, FEV1/FVC), 12-lead ECG, blood tests including aminotranspherase, plasma potassium and glucose level and blood cell count were done. After three months of treatment spirometry was repeated. Evaluation of the ECG, plasma potassium and glucose level was carried out before taking formoterol and 1 hour afterwards.
Results. FVC after 3 month treatment increased significantly in all subjects (p = 0.003). FEV1 and FEV1/FVC changes did not reach significant level. There were no significant changes in the ECG after 3 month observation, neither any changes in the ECG performed 1 hour after administering the drug. Plasma potassium and glucose level did not change significantly after 3 months. However, the fall of potassium 1 hour after taking formoterol was significant (p=0.0001), so was the increase of the glucose level (p=0.01). All subjects reported decreased use of rescue medication, three had tremor after taking the drug.
Conclusion. Formoterol proved to be well-tolerated and helpful in maintenance treatment of mild asthma. There is no evidence of dangerous adverse effects of formoterol during three month treatment. Alergia Astma Immunologia, 2002, 7(4), 223-227


keywords: astma, formoterol, b2-mimetyki dlugo dzialajace, asthma, formoterol, long-acting b2-agonists

pages: from 223 to 227



estimated time of download (80 kB)
broadband speed:561282565121024[kbps]
time:176422[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.